Johnson & Johnson (JNJ) a pharmaceutical, biotechnology, and medical technologies corporation, on Thursday announced positive results from the Phase 3 Vivacity-MG3 study of nipocalimab, an investigational FcRn blocker, in patients with generalized myasthenia gravis or gMG.
The study demonstrated that nipocalimab led to a significant and sustained improvement in disease control over 24 weeks, with a 75% reduction in autoantibody levels.
Notably, the combination of nipocalimab and standard care showed a greater reduction in the MG-ADL score compared to placebo, offering substantial clinical benefit for patients.
Nipocalimab was well-tolerated with a safety profile similar to placebo, with a discontinuation rate of 5.1% compared to 7.1% for placebo.
The results from the Vivacity-MG3 study support the drug's potential as a targeted treatment for gMG, a debilitating autoimmune disease affecting around 700,000 people worldwide.
Johnson & Johnson has submitted a Biologics License Application or BLA to the U.S. FDA and a Marketing Authorisation Application or MAA to the EMA, with the drug receiving U.S. FDA Priority Review for gMG.
The data positions nipocalimab as a promising therapeutic option for gMG patients, as it addresses the underlying cause of the disease by reducing harmful autoantibodies.
Currently, JNJ is trading at $146.84 up by 1.06%.
For comments and feedback: editorial@rttnews.com